DeMuth Peter 4
4 · Elicio Therapeutics, Inc. · Filed Dec 18, 2024
Insider Transaction Report
Form 4
DeMuth Peter
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-12-16$4.41/sh+381$1,680→ 381 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-16−381→ 0 totalExercise: $4.41Exp: 2024-12-18→ Common Stock (381 underlying)
Footnotes (1)
- [F1]The stock option vested and became exercisable as to (i) 25% of the options on the first anniversary of the grant date or December 18, 2015, and (ii) with the remaining shares vesting at a rate of 2.0833% at the end of each month thereafter.